Regulatory T Cells Recruited through CCL22/CCR4 Are Selectively Activated in Lymphoid Infiltrates Surrounding Primary Breast Tumors and Lead to an Adverse Clinical Outcome
Top Cited Papers
Open Access
- 1 March 2009
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 69 (5) , 2000-2009
- https://doi.org/10.1158/0008-5472.can-08-2360
Abstract
Immunohistochemical analysis of FOXP3 in primary breast tumors showed that a high number of tumor-infiltrating regulatory T cells (Ti-Treg) within lymphoid infiltrates surrounding the tumor was predictive of relapse and death, in contrast to those present within the tumor bed. Ex vivo analysis showed that these tumor-infiltrating FOXP3+ T cells are typical Treg based on their CD4+CD25highCD127lowFOXP3+ phenotype, their anergic state on in vitro stimulation, and their suppressive functions. These Ti-Treg could be selectively recruited through CCR4 as illustrated by (a) selective blood Treg CCR4 expression and migration to CCR4 ligands, (b) CCR4 down-regulation on Ti-Treg, and (c) correlation between Ti-Treg in lymphoid infiltrates and intratumoral CCL22 expression. Importantly, in contrast to other T cells, Ti-Treg are selectively activated locally and proliferate in situ, showing T-cell receptor engagement and suggesting specific recognition of tumor-associated antigens (TAA). Immunohistochemical stainings for ICOS, Ki67, and DC-LAMP show that Ti-Treg were close to mature DC-LAMP+ dendritic cells (DC) in lymphoid infiltrates but not in tumor bed and were activated and proliferating. Furthermore, proximity between Ti-Treg, CD3+, and CD8+ T cells was documented within lymphoid infiltrates. Altogether, these results show that Treg are selectively recruited within lymphoid infiltrates and activated by mature DC likely through TAA presentation, resulting in the prevention of effector T-cell activation, immune escape, and ultimately tumor progression. This study sheds new light on Treg physiology and validates CCR4/CCL22 and ICOS as therapeutic targets in breast tumors, which represent a major health problem. [Cancer Res 2009;69(5):2000–9]Keywords
All Related Versions
This publication has 46 references indexed in Scilit:
- Two Functional Subsets of FOXP3+ Regulatory T Cells in Human Thymus and PeripheryImmunity, 2008
- A Multidisciplinary Approach to the Management of Breast Cancer, Part 1: Prevention and DiagnosisMayo Clinic Proceedings, 2007
- Altering the distribution of Foxp3+ regulatory T cells results in tissue-specific inflammatory diseaseThe Journal of Experimental Medicine, 2007
- CCR4-dependent regulatory T cell function in inflammatory bowel diseaseThe Journal of Experimental Medicine, 2007
- CD4+CD25+ Regulatory T-Cell Frequency in HER-2/neu(HER)-Positive and HER-Negative Advanced-Stage Breast Cancer PatientsClinical Cancer Research, 2007
- FOXP3+ Regulatory T Cells Affect the Development and Progression of HepatocarcinogenesisClinical Cancer Research, 2007
- Regulatory T cells, tumour immunity and immunotherapyNature Reviews Immunology, 2006
- IPC: Professional Type 1 Interferon-Producing Cells and Plasmacytoid Dendritic Cell PrecursorsAnnual Review of Immunology, 2005
- Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1ahighCD86−Langerin‐ and CD1a+CD86+Langerin+ phenotypesInternational Journal of Cancer, 2004
- The Inducible CXCR3 Ligands Control Plasmacytoid Dendritic Cell Responsiveness to the Constitutive Chemokine Stromal Cell–derived Factor 1 (SDF-1)/CXCL12The Journal of Experimental Medicine, 2003